
4-26501  
J007 Rec'd PCT/PTOPCT  
24 APR 2001

PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER PF-0627 USN
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. of known sec 37 CFR (1.5) TO BE ASSIGNED 09/830320
INTERNATIONAL APPLICATION NO. PCT/US99/25458	INTERNATIONAL FILING DATE 28 October 1999	PRIORITY DATE CLAIMED 28 October 1998
TITLE OF INVENTION GROWTH FACTOR RELATED MOLECULES		
APPLICANT(S) FOR DO/EO/US INCYTE PHARMACEUTICALS, INC.; TANG, Y. Tom; YUE, Henry; HILLMAN, Jennifer L.; CORLEY, Neil C.; GUEGLER, Karl J.; BAUGHN, Mariah R.; AU-YOUNG, Janice		
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <ol style="list-style-type: none"><li><input checked="" type="checkbox"/> This is the <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li><li><input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li><li><input type="checkbox"/> This is an express request to promptly begin national examination procedures (35 U.S.C. 371 (f)).</li><li><input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).</li><li><input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))<ol style="list-style-type: none"><li><input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau)</li><li><input type="checkbox"/> has been communicated by the International Bureau.</li><li><input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li></ol></li><li><input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</li><li><input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))<ol style="list-style-type: none"><li><input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li><li><input type="checkbox"/> have been communicated by the International Bureau.</li><li><input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li><li><input checked="" type="checkbox"/> have not been made and will not be made.</li></ol></li><li><input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li><li><input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</li><li><input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li></ol>		
Items 11 to 16 below concern document(s) or information included:		
<ol style="list-style-type: none"><li><input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li><li><input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.27 and 3.31 is included.</li><li><input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</li><li><input type="checkbox"/> A substitute specification.</li><li><input type="checkbox"/> A change of power of attorney and/or address letter.</li><li><input checked="" type="checkbox"/> Other items or information:  1) Transmittal Letter (2 pp, in duplicate) 2) Return Postcard 3) Express Mail Label No.: <u>EL 856 113 243 US</u> 4) Request to Transfer</li></ol>		

<b>09/830320</b> U.S. APPLICATION NO. (if known, see 37 CFR 1.5) <b>TO BE ASSIGNED</b>		INTERNATIONAL APPLICATION NO.: <b>PCT/US99/ 25458</b>	ATTORNEY'S DOCKET NUMBER <b>PF-0627 USN</b>
17. <input type="checkbox"/> The following fees are submitted: <b>BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):</b> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO.....\$1000.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO..\$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$710.00 <input checked="" type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4).....\$690.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4).....\$100.00			
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$690.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total Claims	20 =	0	X \$ 18.00
Independent Claims	2 =	0	X \$ 80.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)		+ \$270.00	\$
TOTAL OF ABOVE CALCULATIONS =		\$690.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.		\$	
SUBTOTAL =		\$690.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		\$	
TOTAL NATIONAL FEE =		\$690.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by the appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property		\$	
TOTAL FEES ENCLOSED =		\$690.00	
Amount to be Refunded:		\$	
Charged:		\$	
<p>a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed.</p> <p>b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>09-0108</u> in the amount of \$ <u>690.00</u> to cover the above fees.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any          overpayment to Deposit Account No. <u>09-0108</u>. A duplicate copy of this sheet is enclosed.</p> <p><b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must          be filed and granted to restore the application to pending status.</b></p> <p>SEND ALL CORRESPONDENCE TO:</p> <p>INCYTE GENOMICS, INC.          3160 Porter Drive          Palo Alto, CA 94304</p> <div style="text-align: center; margin-top: 20px;">           SIGNATURE       </div> <p style="text-align: center;">NAME: Diana Hamlet-Cox</p> <p style="text-align: center;">REGISTRATION NUMBER: 33,302</p> <p style="text-align: center;">DATE: <u>24</u> April 2001</p>			